The first CRISPR gene-editing drug, designed to treat blood disorders, could be on the market by 2023. Here’s what it means for the future of drug development.
The central dogma of molecular biology explains the flow of genetic information, from DNA to RNA, to make a functional product, a protein.
This Video Explains Central Dogma.
“We are starting to help patients in ways that we did not think were possible,” Thomas Oxley (Mount Sinai Hospital, New York, USA) tells NeuroNews, referring to the potential of brain-computer interface (BCI) technology. Alongside his role as a vascular and interventional neurologist, Oxley is chief executive officer of Synchron, developer of the Stentrode motor neuroprosthesis. The Stentrode is an implantable BCI device that, according to Oxley, is the first of its kind to be in the early feasibility clinical stage in the USA following US Food and Drug Administration (FDA) approval of Synchron’s investigational device exemption (IDE) application last month. Speaking to NeuroNewsfollowing a presentation on the topic at the Society of NeuroInterventional Surgery’s 18thannual meeting (SNIS; 26–29 July 2021, Colorado Springs, USA and virtual), Oxley gives an overview of the COMMAND early feasibility study, anticipates key results, and considers more generally how BCI technology could shape the future of deep brain stimulation.
Cosmologist, noted author, Astronomer Royal and recipient of the 2015 Nierenberg Prize for Science in the Public Interest Lord Martin Rees delivers a thought-provoking and insightful perspective on the challenges humanity faces in the future beyond 2050. [3/2016] [Show ID: 30476]
Frontiers of Knowledge.
(https://www.uctv.tv/frontiers-of-knowledge)
Continue reading “Looking Beyond 2050 — On Earth and in Space with Lord Martin Rees” »
An experimental drug restored brain synapses in two mouse models of Alzheimer’s disease, raising hopes that it could help revive cognitive function in human dementia patients, Yale University researchers report June 1 in the journal Science Translational Medicine.
While much research in Alzheimer’s has centered on reducing levels of beta-amyloid plaque in the brain that is a hallmark of the disease, recent studies have suggested that immune system response in the brain also plays a role in memory loss in patients.
Some scientists now believe that cognitive decline in Alzheimer’s patients results from a loss of synaptic connections between neurons caused by a steady accumulation of beta-amyloid protein in the brain which in turn unleashes a chronic immune system response to the intruder. The end stages of the disease lead to the death of neurons.
One person has died and 22 people have been hospitalized in a listeria outbreak, with most of the infected people having been in Florida about a month before they became sick, the federal authorities said Thursday.
A food source has not been identified as the cause of the outbreak, which has sickened people across 10 states from January 2021 through June 12, 2022, the Centers for Disease Control and Prevention said in a statement.
It typically takes three or four weeks to determine if an illness is tied to an outbreak, so recent cases may not be reported in the data. The true number of sick people is most likely higher because some people recover without medical care, the agency said.
The DNA-altering technology has revolutionized life sciences research and is making strides in potential one-and-done treatments for sickle cell disease, genetic liver conditions, and more.
Join the audience for a live webinar at 3 p.m. BST on 5 July 2022 exploring the most recent real-time adaptive radiotherapy developments and the new cardiac radioablation treatment.
Stereotactic radioablation is a novel, non-invasive treatment option for cardiac arrhythmias. The heart is dose sensitive and its motion contributes significantly to dose delivery uncertainties.
A Northwestern University-led team of researchers has developed a small, soft, flexible implant that relieves pain on demand and without the use of drugs. The first-of-its-kind device could provide a much-needed alternative to opioids and other highly addictive medications.
Scientists at Northwestern University have developed a small, flexible implant that can relieve pain on-demand and disappear into the body’s biofluids.
